The Changing Landscape of Clostridioides difficile Infections

The Changing Landscape of Clostridioides difficile Infections

The Changing Landscape of Clostridioides difficile Infections

Learn how you can identify CDI patients early in the disease process and predict which patients will experience a recurrence.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Approximately half a million Americans are diagnosed with Clostridioides difficile infections (CDI) each year. About 1 in 5 patients with CDI who are treated and cured will still experience a return of the infection within 2 months. Additionally, approximately 1 in every 10 to 20 patients with CDI will be admitted to the ICU, have a colectomy, or even die from the disease. As it stands currently, physicians do not have the means to identify who will and will not have recurrence, and they also lack the tools needed to identify these patients early in the disease process. 

    In this discussion, Drs. Kevin Garey and Krishna Rao take a closer look at appropriate, personalized treatment plans for patients with or at risk for recurrent CDI.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Kevin W. Garey, PharmD, MS

    Professor and Chair
    University of Houston College of Pharmacy
    Houston, TX

    Consulting Fees: Summit Pharmaceuticals
    Contracted Research: Acurx, Paratek, Summit Pharmaceuticals, Tetraphase

    A. Krishna Rao, MD, MS
    Assistant Professor
    Division of Infectious Diseases
    Department of Internal Medicine
    University of Michigan Medical School
    Ann Arbor, MI

    Consulting Fees: Bio-K+ International Inc., Roche Molecular Systems, Inc.
    Contracted Research: Merck & Co., Inc.

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Elizabeth Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Summarize IDSA guidelines for evidence-based management of patients with CDI.
    • Develop appropriate, personalized treatment plans for patients with or at risk for recurrent CDI.
  • Target Audience

    This activity is designed to meet the educational needs of infectious disease physicians, nurse practitioners, nurses, pharmacists, and hospitalists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free